Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 40.00
Ask: 41.00
Change: -1.00 (-2.41%)
Spread: 1.00 (2.50%)
Open: 41.50
High: 41.50
Low: 40.50
Prev. Close: 41.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

14 Jun 2016 12:18

RNS Number : 1559B
Venture Life Group PLC
14 June 2016
 

Venture Life Group PLC

 

("Venture Life" or the "Company")

 

Director/PDMR Shareholding

 

Bracknell, UK - 14 June 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 13 June 2016 that Ms. Sharon Collins, the Commercial Director of the Company, has undertaken dealings in 27,030 ordinary shares of 0.3p each in the Company ("Ordinary Shares"), transferring 26,430 of her current holding of Ordinary Shares to her ISA, and selling and re-purchasing 600 Ordinary Shares to be held in her non-ISA account.

 

The dealings were made between 8 June 2016 and 13 June 2016 as set out below:

 

Date

Dealing type

Number of Ordinary Shares sold

Number of Ordinary Shares purchased

Price (p)

8 June 2016

Sale

26,600

-

57.00

8 June 2016

Purchased to ISA

-

26,000

57.10

9 June 2016

Sale

430

-

57.00

9 June 2016

Purchased to ISA

-

430

57.00

Total sold

27,030

-

 

Total purchased to ISA

-

26,430

 

 

 

 

 

 

13 June 2016

Purchase

-

600

59.49

Total dealings

27,030

27,030

 

 

Following the dealings, Ms. Collins's beneficial interest in the Company remains unchanged at 1,582,417 Ordinary Shares, representing approximately 4.3% of the issued share capital in the Company.

 

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer +44 (0)1344 742 870

James Hunter, Chief Financial Officer

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500

Peter Steel

Duncan Monteith Corporate Finance

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick

Brian Alexander +44 (0)20 7929 5599

 

 

 

 

About Venture Life

 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLLRDISLIR
Date   Source Headline
1st Mar 201612:07 pmRNSResult of General Meeting and Issue of Equity
18th Feb 201610:20 amRNSDirectorate Change
12th Feb 20165:38 pmRNSCircular Publication & Notice of General Meeting
12th Feb 201612:11 pmRNSResults of Placing to Partially Fund Acquisition
12th Feb 20167:00 amRNSProposed Placing and issue of Convertible Bonds
13th Jan 20167:00 amRNSProduct Launch
23rd Dec 20157:38 amRNSTrading Update
29th Sep 20157:00 amRNSInterim Results
9th Sep 20157:00 amRNSNotice of Results
9th Jul 20157:00 amRNSPre-Close Trading Statement
10th Jun 201511:41 amRNSAGM Statement
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
22nd May 20157:00 amRNSPDMR Shareholding
15th Apr 20157:00 amRNS2014 Annual Report and Dividend Timetable
25th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSSale of trademarks: manufacturing agreement signed
26th Jan 20157:00 amRNS30-year exclusive distribution deal signed
9th Dec 20147:00 amRNSBenecol Supplement Capsule Sale Malta
4th Dec 201411:54 amRNSHolding(s) in Company
28th Nov 20147:00 amRNSShare Placing
19th Nov 20147:00 amRNSAppointment of Nominated Adviser and Broker
10th Oct 20147:00 amRNSDirector's Dealings
8th Oct 20147:00 amRNSDirector Dealings
6th Oct 20147:00 amRNSDirectors' Dealings
1st Oct 20147:00 amRNSInvestor Forum
29th Sep 20147:00 amRNSInterim Results
23rd Sep 20147:00 amRNSNew distribution agreements
5th Sep 20147:00 amRNSNotice of Interim Results
6th Aug 20147:00 amRNSNew Product Development and Board Change
7th Jul 20147:00 amRNSNew distribution agreement signed
30th Jun 201412:09 pmRNSAGM Statement
30th Jun 20147:00 amRNSTotal Voting Rights
25th Jun 20147:00 amRNSNew distribution agreements signed
17th Jun 20147:00 amRNSAppointment of Non-Executive Director
13th Jun 20149:44 amRNSHolding(s) in Company
5th Jun 20147:01 amRNSIssue of new shares
5th Jun 20147:00 amRNSFinal Results
23rd Apr 20147:00 amRNSNew Distribution Agreement
28th Mar 20148:00 amRNSAdmission to AIM and Acquisition of Biokosmes Srl

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.